为深入贯彻习近平总书记关于激发涌现更多专精特新中小企业的重要指示批示精神，工业和信息化部开展 了2025年专精特新"小巨人"企业认定和复核工作，已完成相关审核。10月20日，各地陆续公示了 第七批专 精特新"小巨人"企业 和 2025年专精特新"小巨人"复核通过企业名单 。 在各省市中，新申请企业数量排在前五的是 江苏省、深圳市、广东省、浙江省、北京市 添加客服微信： myrobotics ，备注" 参会人员 "，邀请进入会议群。 缴费成功后请务必将 参会回执 发送邮件至编辑部邮箱（ cims_journal@qq.com ） 点击蓝字下载参会回执文件： 附件：参会回执.docx | 序号 | 省份 | 企业数量-新申请 | 企业数量-复核 | | --- | --- | --- | --- | | 1 | 辽宁省 | 22 | 42 | | 2 | 黑龙江省 | 5 | 14 | | 3 | 山西省 | 17 | 35 | | 4 | 河北省 | 56 | 135 | | 5 | 广东省 | 344 | 159 | | 6 | 江苏省 | 807 | 400 | | 7 | 安徽省 | 153 | 236 ...

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its stock performance and revenue, driven by advancements in cell immunotherapy, recombinant proteins, and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [1][3][9]. Group 1: Company Performance - On October 21, the company's stock rose by 4.63%, with a trading volume of 155 million yuan and a market capitalization of 10.235 billion yuan [1]. - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%, and a net profit of 83.804 million yuan, up 47.81% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 2: Product Development and Market Position - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings related to cell and gene therapy [2]. - It has developed high-quality recombinant proteins for various disease targets and biomarkers, supporting the entire process of biopharmaceutical research and production [2]. - The company is actively developing products related to monkeypox virus, having already launched several recombinant proteins, antibodies, and test kits to aid in vaccine and therapeutic drug development [2]. Group 3: Industry Recognition and Financial Impact - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the yuan [4]. - The company operates in the pharmaceutical and biotechnology sector, focusing on bioproducts and related concepts, including Alzheimer's and monkeypox [9].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank amid the depreciation of the RMB. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other sources [8] - As of August 29, the number of shareholders is 12,700, a decrease of 0.43%, while the average circulating shares per person increased by 0.43% to 33,056 shares [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance - On October 21, the company's stock rose by 1.91%, with a trading volume of 62.88 million yuan and a turnover rate of 0.78%, leading to a total market capitalization of 8.08 billion yuan [1] - The average trading cost of the stock is 20.50 yuan, with a current support level at 19.05 yuan [7]

Core Viewpoint - The company, Hema Electric Power Electronics Co., Ltd., is experiencing fluctuations in stock performance and is involved in the photovoltaic and energy storage sectors, benefiting from the depreciation of the RMB and plans for share repurchase and increase in holdings by major shareholders [1][3]. Company Overview - Hema Electric Power Electronics Co., Ltd. specializes in the research, manufacturing, and sales of photovoltaic inverters, energy storage products, and electrical equipment [2][7]. - The company's main products include micro-inverters, monitoring equipment, distributed photovoltaic systems, modular inverters, and energy storage systems [2][7]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2]. Financial Performance - For the first half of 2025, the company achieved a revenue of 1.005 billion yuan, representing a year-on-year growth of 10.78%, while the net profit attributable to shareholders decreased by 91.33% to 16.27 million yuan [8]. - As of June 30, the company had 9,849 shareholders, a decrease of 5.73% from the previous period, with an average of 12,597 circulating shares per person, an increase of 6.08% [8]. Market Position and Trends - The company has a significant overseas revenue share of 64.25%, benefiting from the depreciation of the RMB [3]. - The stock has shown a slight decline of 0.06% recently, with a trading volume of 73.93 million yuan and a turnover rate of 0.56%, leading to a total market capitalization of 13.273 billion yuan [1]. Shareholder Activity - On March 5, 2025, Hangkai Holdings Group announced plans to increase its holdings in Hema Electric, with an investment amount between 111.5 million yuan and 223 million yuan, funded by self-owned capital and special loans [3].

Core Viewpoint - The innovation vitality of small and medium-sized enterprises (SMEs) can be stimulated by promoting their deep participation in the industrial and supply chains, enhancing their supporting capabilities [1][4] Group 1: Current Performance of SMEs - In the first eight months of this year, the added value of industrial SMEs increased by 7.6% year-on-year, outpacing large enterprises by 3.3 percentage points, indicating stable overall operation and a notable surge in innovation vitality [2] - The proportion of effective invention patents from independent R&D among SMEs reached 75.3% in 2024, up by 3.9 percentage points from the previous year [2] - The rate of industrialization for invention patents among small and micro enterprises hit new highs at 57.8% and 36.7%, respectively [2] - Specialized and innovative SMEs, referred to as "little giants," hold 32.74 million invention patents, accounting for 11% of the total [2] Group 2: Support for Innovation and Digital Transformation - To enhance innovation, a supportive and inclusive environment is essential, requiring sustained capital investment and the establishment of a national SME development fund to attract more social capital [3] - The government should select replicable digital transformation solutions to guide SMEs, addressing their challenges in transitioning to digital operations [3] - Financial measures such as fiscal subsidies, tax reductions, and special funds should be implemented to meet the funding needs of SMEs during their digital transformation [3] Group 3: Role of SMEs in Economic Development - SMEs are crucial for driving innovation, promoting employment, and improving livelihoods, with their health directly impacting the resilience of the economy [4] - Local governments and departments should focus on addressing the urgent issues faced by SMEs, creating mechanisms to foster the growth of specialized and innovative SMEs [4]

Core Points - Longi Technology's stock price increased by 2.02% on October 21, reaching 60.60 CNY per share, with a trading volume of 1.11 billion CNY and a market capitalization of 7.226 billion CNY [1] - The company has seen a year-to-date stock price increase of 97.23%, but has experienced a decline of 9.82% over the last five trading days [1] - Longi Technology's main business involves the research, production, and sales of new functional materials, specifically permanent magnetic ferrite [1] Financial Performance - For the first half of 2025, Longi Technology reported a revenue of 591 million CNY, representing a year-on-year growth of 6.36%, and a net profit attributable to shareholders of 85.252 million CNY, up 31.82% year-on-year [2] - The company has distributed a total of 134 million CNY in dividends since its A-share listing, with 70.342 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Longi Technology had 18,300 shareholders, a decrease of 0.99% from the previous period, with an average of 4,474 circulating shares per shareholder, an increase of 1.00% [2] - The fifth largest circulating shareholder is Huashang New Trend Preferred Mixed Fund, which holds 1.1 million shares as a new entrant, while Huashang Credit Enhanced Bond A and Huashang Strategy Preferred Mixed A have exited the top ten circulating shareholders list [3]

Core Viewpoint - Guangli Microelectronics has shown significant growth in revenue and profit, indicating strong performance in the semiconductor industry, particularly in EDA software and testing equipment [2][3]. Financial Performance - As of June 30, Guangli Microelectronics achieved a revenue of 246 million yuan, representing a year-on-year growth of 43.17% [2]. - The net profit attributable to shareholders reached 15.68 million yuan, marking a substantial increase of 518.42% compared to the previous period [2]. - Since its A-share listing, the company has distributed a total of 217 million yuan in dividends [3]. Stock Market Activity - On October 21, Guangli Microelectronics' stock price increased by 2.04%, reaching 77.04 yuan per share, with a trading volume of 255 million yuan [1]. - The stock has appreciated by 48.66% year-to-date, although it has experienced a decline of 6.04% over the last five trading days [1]. - The company has a total market capitalization of 15.43 billion yuan [1]. Shareholder Information - As of June 30, the number of shareholders increased to 29,300, up by 18.89% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 15.89% to 3,667 shares [2]. - Notable institutional investors include Noan Optimized Allocation Mixed A and Guolian An Zhongzheng All-Index Semiconductor Products and Equipment ETF, with both increasing their holdings [3]. Business Overview - Guangli Microelectronics, established on August 12, 2003, specializes in the design, development, and service of integrated circuit EDA software and wafer-level electrical testing equipment [1]. - The company's revenue composition includes 62.40% from testing equipment and accessories, 37.00% from software development and licensing, and 0.60% from testing services and others [1]. - The company operates within the computer software development sector, focusing on vertical application software, and is involved in several key industry concepts such as photolithography machines and artificial intelligence [1].

Core Viewpoint - The stock of Beijing Eight Billion Space Technology Co., Ltd. has shown fluctuations in price and trading volume, with a recent increase of 2.01% and a market capitalization of 4.719 billion yuan, indicating investor interest and activity in the company [1]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 415 million yuan, representing a year-on-year growth of 10.63%, while the net profit attributable to shareholders decreased by 37.90% to 30.8724 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 128 million yuan, with 41.2998 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 17.18% to 9,597, while the average circulating shares per person decreased by 14.66% to 14,012 shares [2]. - The top ten circulating shareholders include notable funds, with specific reductions in holdings observed for certain funds [3]. Stock Performance - The stock price has increased by 6.66% year-to-date, but has seen a decline of 5.26% over the last five trading days and 7.17% over the last twenty days [1]. - The stock's trading volume indicates a net inflow of 4.9344 million yuan from main funds, with significant buying activity noted [1]. Business Overview - The company specializes in the research, development, production, and sales of display liquid crystal materials, with a revenue composition primarily from mixed liquid crystals (90.87%) [1]. - The company is categorized under the electronic and optical optoelectronic panel industry, with involvement in various concept sectors including lithium hexafluorophosphate and OLED [1].

Core Points - The stock price of Shenyu Co., Ltd. increased by 2.01% on October 21, reaching 38.10 CNY per share, with a trading volume of 1.10 billion CNY and a market capitalization of 6.836 billion CNY [1] - Year-to-date, the stock has declined by 30.63%, with a 2.81% drop over the last five trading days and a 4.20% drop over the last 20 days [1] - The company specializes in the research, production, and sales of RF coaxial cables, with main business revenue composition: coaxial cables 81.83%, others 9.78%, and gold wire products 8.39% [1] Financial Performance - For the first half of 2025, Shenyu Co., Ltd. achieved operating revenue of 396 million CNY, a year-on-year increase of 0.46%, while net profit attributable to shareholders decreased by 41.54% to 33.445 million CNY [2] - The company has distributed a total of 185 million CNY in dividends since its A-share listing, with 106 million CNY distributed in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 44,100, up by 9.73%, with an average of 2,814 circulating shares per person, a decrease of 8.71% [2] - The third-largest circulating shareholder is the Gold Stock ETF (517520), which holds 676,400 shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]

Core Insights - Donghua Testing's stock price increased by 34.57% year-to-date, with a recent rise of 3.26% over the past five trading days [1] - The company reported a revenue of 283 million yuan for the first half of 2025, reflecting a year-on-year growth of 2.44% [2] - The main business revenue composition includes 71.99% from structural mechanics performance testing systems, 12.89% from structural safety online monitoring, and 10.54% from electrochemical workstations [1] Financial Performance - As of June 30, 2025, Donghua Testing achieved a net profit of 76.39 million yuan, marking a 2.80% increase year-on-year [2] - The company has distributed a total of 147 million yuan in dividends since its A-share listing, with 66.58 million yuan distributed over the last three years [3] Shareholder Information - The number of shareholders increased by 4.20% to 15,100 as of June 30, 2025, with an average of 5,388 circulating shares per person, a decrease of 4.03% [2] - Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 936,400 shares, down by 19.95% from the previous period [3]